Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study.

Background: Janus kinase inhibitor (JAKi) therapy has revolutionized the treatment landscape for alopecia areata (AA); however, access may be limited by a lack of insurance coverage and high out-of-pocket costs.

Objective: We aimed to evaluate real-world patient experiences regarding access to JAKi therapy.

Methods: We conducted an online patient-centered survey using the National Alopecia Areata Foundation listserv.